Cargando…

Medical Management of Parkinson’s Disease: Focus on Neuroprotection

Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties...

Descripción completa

Detalles Bibliográficos
Autores principales: Boll, Marie-Catherine, Alcaraz-Zubeldia, Mireya, Rios, Camilo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131725/
https://www.ncbi.nlm.nih.gov/pubmed/22131943
http://dx.doi.org/10.2174/157015911795596577
_version_ 1782207751418544128
author Boll, Marie-Catherine
Alcaraz-Zubeldia, Mireya
Rios, Camilo
author_facet Boll, Marie-Catherine
Alcaraz-Zubeldia, Mireya
Rios, Camilo
author_sort Boll, Marie-Catherine
collection PubMed
description Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties in preclinical experiments and evidence-based efficacy in human subjects. To this date, neuroprotection has never been solidly proven in clinical trials but recent adequate markers and/or strategies to study and promote this important goal are described. A myriad of compounds with protective properties in cell cultures and animal models yield to few treatments in clinical practice. At present, markers of neuronal vitality, disease modifying effects and long term clinical stability are the elements searched for in clinical trials. This review highlights new strategies to monitor patients with PD. Currently, neuroprotection in subjects has not been solidly achieved for selegiline and pramipexole; however, a recent rasagiline trial design is showing new indications of disease course modifying effects. In neurological practice, it is of utmost importance to take into account the potential neuroprotection exerted by a treatment in conjunction with its symptomatic efficacy.
format Online
Article
Text
id pubmed-3131725
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Bentham Science Publishers Ltd
record_format MEDLINE/PubMed
spelling pubmed-31317252011-12-01 Medical Management of Parkinson’s Disease: Focus on Neuroprotection Boll, Marie-Catherine Alcaraz-Zubeldia, Mireya Rios, Camilo Curr Neuropharmacol Article Neuroprotection refers to the protection of neurons from excitotoxicity, oxidative stress and apoptosis as principal mechanisms of cell loss in a variety of diseases of the central nervous system. Our interest in Parkinson’s disease (PD) treatment is focused on drugs with neuroprotective properties in preclinical experiments and evidence-based efficacy in human subjects. To this date, neuroprotection has never been solidly proven in clinical trials but recent adequate markers and/or strategies to study and promote this important goal are described. A myriad of compounds with protective properties in cell cultures and animal models yield to few treatments in clinical practice. At present, markers of neuronal vitality, disease modifying effects and long term clinical stability are the elements searched for in clinical trials. This review highlights new strategies to monitor patients with PD. Currently, neuroprotection in subjects has not been solidly achieved for selegiline and pramipexole; however, a recent rasagiline trial design is showing new indications of disease course modifying effects. In neurological practice, it is of utmost importance to take into account the potential neuroprotection exerted by a treatment in conjunction with its symptomatic efficacy. Bentham Science Publishers Ltd 2011-06 /pmc/articles/PMC3131725/ /pubmed/22131943 http://dx.doi.org/10.2174/157015911795596577 Text en © Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Boll, Marie-Catherine
Alcaraz-Zubeldia, Mireya
Rios, Camilo
Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title_full Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title_fullStr Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title_full_unstemmed Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title_short Medical Management of Parkinson’s Disease: Focus on Neuroprotection
title_sort medical management of parkinson’s disease: focus on neuroprotection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131725/
https://www.ncbi.nlm.nih.gov/pubmed/22131943
http://dx.doi.org/10.2174/157015911795596577
work_keys_str_mv AT bollmariecatherine medicalmanagementofparkinsonsdiseasefocusonneuroprotection
AT alcarazzubeldiamireya medicalmanagementofparkinsonsdiseasefocusonneuroprotection
AT rioscamilo medicalmanagementofparkinsonsdiseasefocusonneuroprotection